NO20050018L - Lasofoxifentabletter og belegg - Google Patents

Lasofoxifentabletter og belegg

Info

Publication number
NO20050018L
NO20050018L NO20050018A NO20050018A NO20050018L NO 20050018 L NO20050018 L NO 20050018L NO 20050018 A NO20050018 A NO 20050018A NO 20050018 A NO20050018 A NO 20050018A NO 20050018 L NO20050018 L NO 20050018L
Authority
NO
Norway
Prior art keywords
lasofoxifene
tablets
coatings
active ingredient
triacetin
Prior art date
Application number
NO20050018A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20050018L publication Critical patent/NO20050018L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet farmasøytiske preparater hvor lasofoxifen benyttes som en aktiv ingrediens, som har ensartet legemiddelfordeling og styrke og som inneholder et silisiumdioksyd for å redusere tap av den aktive ingrediens under fremstillingsprosessen, og metoder for fremstilling av slike preparater. Triacetin som plastiseringsmiddel i overtrekk, ble vist å gi god stabilitet for lasofoxifen.
NO20050018A 2002-07-10 2005-01-03 Lasofoxifentabletter og belegg NO20050018L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10
PCT/IB2003/003074 WO2004006895A1 (en) 2002-07-10 2003-06-30 Lasofoxifene tablet and its coating

Publications (1)

Publication Number Publication Date
NO20050018L true NO20050018L (no) 2005-01-12

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050018A NO20050018L (no) 2002-07-10 2005-01-03 Lasofoxifentabletter og belegg

Country Status (36)

Country Link
US (2) US20040057992A1 (no)
EP (1) EP1534248B1 (no)
JP (2) JP4446446B2 (no)
KR (1) KR100782693B1 (no)
CN (1) CN100344278C (no)
AP (1) AP2005003201A0 (no)
AR (1) AR040434A1 (no)
AT (1) ATE550017T1 (no)
AU (1) AU2003247017B2 (no)
BR (1) BR0312563A (no)
CA (1) CA2489407C (no)
CY (1) CY1112892T1 (no)
DK (1) DK1534248T3 (no)
EA (1) EA007268B1 (no)
EC (1) ECSP055528A (no)
ES (1) ES2395123T3 (no)
HK (1) HK1077747A1 (no)
HN (1) HN2003000206A (no)
HR (1) HRP20041196A2 (no)
IL (2) IL165746A0 (no)
IS (1) IS7594A (no)
MA (1) MA27318A1 (no)
MX (1) MXPA05000394A (no)
NO (1) NO20050018L (no)
NZ (1) NZ537278A (no)
OA (1) OA12883A (no)
PA (1) PA8576201A1 (no)
PE (1) PE20040104A1 (no)
PL (1) PL374913A1 (no)
PT (1) PT1534248E (no)
SI (1) SI1534248T1 (no)
TN (1) TNSN05006A1 (no)
TW (1) TW200406222A (no)
UY (1) UY27886A1 (no)
WO (1) WO2004006895A1 (no)
ZA (1) ZA200410196B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
WO2006105806A1 (en) * 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
US8192761B2 (en) * 2005-04-26 2012-06-05 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
AU2008218186C1 (en) 2007-02-23 2014-07-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2587805C (en) * 2007-04-25 2014-02-18 The Procter & Gamble Company Improved vitamin d content uniformity in pharmaceutical dosage forms
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
KR101633939B1 (ko) * 2007-10-10 2016-06-27 아반토르 퍼포먼스 머티리얼스, 인크. 직접 압축성 고기능성 과립 미세결정 셀룰로스계 부형제, 그의 제조 방법 및 용도
US20090274757A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
AU2009242451C1 (en) * 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
UA114412C2 (uk) * 2011-10-17 2017-06-12 Лексікон Фармасьютікалз, Інк. Тверда дозована форма гіпурату (s)-2-аміно-3-(4-(2-аміно-6-((r)-1-(4-хлор-2-(3-метил-1h-піразол-1-іл)феніл)-2,2,2-трифторетокси)піримідин-4-іл)феніл)пропаноату
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
CN105658209A (zh) * 2013-09-13 2016-06-08 拜耳制药股份公司 含有瑞法美替的药物组合物
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
EP3487482A4 (en) * 2016-07-25 2020-03-04 Canopy Growth Corporation NEW CANNABIS TABLET FORMULAS.
WO2018093484A1 (en) 2016-10-11 2018-05-24 Duke University Lasofoxifene treatment of er+ breast cancer
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) * 2000-03-10 2001-11-14 Pfizer Products Inc. Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
HK1077747A1 (en) 2006-02-24
EP1534248A1 (en) 2005-06-01
EA007268B1 (ru) 2006-08-25
HRP20041196A2 (en) 2005-04-30
OA12883A (en) 2006-09-15
CY1112892T1 (el) 2016-04-13
US20040057992A1 (en) 2004-03-25
EA200401583A1 (ru) 2005-06-30
ECSP055528A (es) 2005-03-10
AR040434A1 (es) 2005-04-06
AU2003247017B2 (en) 2008-03-06
ES2395123T3 (es) 2013-02-08
AU2003247017A1 (en) 2004-02-02
EP1534248B1 (en) 2012-03-21
IL165746A0 (en) 2006-01-15
DK1534248T3 (da) 2012-06-25
PL374913A1 (en) 2005-11-14
HN2003000206A (es) 2004-07-27
TNSN05006A1 (fr) 2007-05-14
MXPA05000394A (es) 2005-03-23
JP2007031451A (ja) 2007-02-08
US7553500B2 (en) 2009-06-30
CN100344278C (zh) 2007-10-24
JP2005535671A (ja) 2005-11-24
IL165746A (en) 2008-12-29
CA2489407C (en) 2009-01-27
UY27886A1 (es) 2004-02-27
JP4446446B2 (ja) 2010-04-07
KR100782693B1 (ko) 2007-12-07
PT1534248E (pt) 2012-05-25
AP2005003201A0 (en) 2005-03-31
CN1668285A (zh) 2005-09-14
CA2489407A1 (en) 2004-01-22
NZ537278A (en) 2007-07-27
BR0312563A (pt) 2005-04-19
SI1534248T1 (sl) 2012-07-31
KR20050017102A (ko) 2005-02-21
ZA200410196B (en) 2006-07-26
US20070110800A1 (en) 2007-05-17
ATE550017T1 (de) 2012-04-15
PA8576201A1 (es) 2004-05-26
MA27318A1 (fr) 2005-05-02
TW200406222A (en) 2004-05-01
PE20040104A1 (es) 2004-02-27
IS7594A (is) 2004-12-13
WO2004006895A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
NO20050018L (no) Lasofoxifentabletter og belegg
TW200745111A (en) New compounds
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
NO20062884L (no) AKT-proteinkinaseinhibitorer
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
TW200621762A (en) Novel compounds
WO2001087839A8 (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20070570L (no) Forbindelser.
TW200606164A (en) New compounds
UA90285C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
DE602004011966D1 (en) Heterocyclylverbindungen
NO20020282L (no) Nytt difenyl-piperidinderivat
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
TW200800984A (en) New compounds
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
IL151359A (en) Esmolol formulation
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
NO20083441L (no) Benzoisoindolderivater for behandling av smerte
WO2004106307A3 (fr) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
WO2004056808A8 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
WO2004056809A8 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
WO2024086246A3 (en) 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application